In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls.
We investigated cytokine levels (interleukin [IL]-1beta, IL-1ra, IL-2, IL-6, tumor necrosis factor [TNF]-alpha, TNF-beta) in plasma and secreted by mitogen-stimulated blood monocytes and lymphocytes; T-cell subsets; and natural killer cell activity in patients with narcolepsy and in human leukocyte antigen (HLA)-DR2 matched controls. The only significant finding was higher IL-6 secretion by monocytes of patients than by those of the HLA-DR2-positive controls. In conclusion, we found no major abnormalities of T-cell function in patients with narcolepsy, but slight alterations of monocyte function deserving further investigation.
Hinze-Selch
D
D
Clinical Institute, Max Planck Institute of Psychiatry, Munich, Germany.
Wetter
T C
TC
Zhang
Y
Y
Lu
H C
HC
Albert
E D
ED
Mullington
J
J
Wekerle
H
H
Holsboer
F
F
Pollmächer
T
T
D000328:Adult; D005260:Female; D015802:HLA-DR2 Antigen / Q000032:analysis*; D006650:Histocompatibility Testing; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008233:Lymphotoxin-alpha / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000276:immunology*; D012795:Sialoglycoproteins / Q000378:metabolism; D012895:Sleep, REM / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015802:HLA-DR2 Antigen; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D008233:Lymphotoxin-alpha; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha